Shares of OpGen, Inc. (NASDAQ:OPGN) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.
Brokers have set a 12-month consensus price objective of $1.50 for the company and are predicting that the company will post ($0.06) earnings per share for the current quarter, according to Zacks. Zacks has also assigned OpGen an industry rank of 163 out of 265 based on the ratings given to related companies.
OPGN has been the topic of several research reports. Zacks Investment Research lowered OpGen from a “buy” rating to a “hold” rating in a report on Wednesday, September 13th. HC Wainwright reaffirmed a “buy” rating and set a $1.00 price objective on shares of OpGen in a report on Monday, September 11th.
An institutional investor recently bought a new position in OpGen stock. Perkins Capital Management Inc. purchased a new position in shares of OpGen, Inc. (NASDAQ:OPGN) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 1,400,000 shares of the medical research company’s stock, valued at approximately $434,000. Perkins Capital Management Inc. owned about 2.72% of OpGen as of its most recent SEC filing. Hedge funds and other institutional investors own 11.83% of the company’s stock.
OpGen (NASDAQ:OPGN) opened at $0.18 on Friday. The stock has a market capitalization of $10.73, a PE ratio of -0.29 and a beta of 0.96. OpGen has a twelve month low of $0.15 and a twelve month high of $1.85. The company has a current ratio of 1.23, a quick ratio of 1.13 and a debt-to-equity ratio of 0.03.
TRADEMARK VIOLATION NOTICE: This news story was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.thelincolnianonline.com/2018/01/14/zacks-analysts-set-1-50-target-price-for-opgen-inc-opgn-updated-updated.html.
OpGen Company Profile
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.